RxDoctor Payments Data

Patrick McManus, MD

Obstetrics & Gynecology · Long Beach, NYNPI 1932180247

Payments from drug & device makers

$6,259in general payments, 2019–2025

Across 335 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • Myovant Sciences Inc.$896
  • AbbVie$834
  • Exeltis, USA Inc.$691
  • Millicent US Inc$491
  • Evofem Biosciences, Inc.$266
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,13098%
  • Education$1292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,259 in reported general payments places this provider in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.

See all obstetrics & gynecology providers in New York

Medicare billing

Part B allowed, 2024
$35,803
Medicare patients
229
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron19$13,274
MounjaroTirzepatide13$12,808
GemtesaVibegron11$8,074
PremarinEstrogens, Conjugated19$8,073
Estradiol91$5,567
ValacyclovirValacyclovir Hcl20$1,098
DivigelEstradiol11$745
Raloxifene Hcl11$625
ProgesteroneProgesterone, Micronized20$335
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$324
Metronidazole15$230
Fluconazole25$131
Ibuprofen13$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$22$13,27419 claims
Sumitomo Pharma America, Inc.Gemtesa$1,137$8,07411 claims
PfizerPremarin$211$8,07319 claims
Vertical Pharmaceuticals, LLCDivigel$52$74511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,673 obstetrics & gynecology providers in New York.

Other obstetrics & gynecology in Long Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →